Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?

Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$144.74M+52.0%	-$301.74M-712%	$49.27M+125%	-$198.38M-126%
Depreciation and amortization	$525K-41.9%	$904K-16.9%	$1.09M+123%	$487K+837%
Stock-based compensation	$27.65M-16.3%	$33.04M-11.1%	$37.16M+71.1%	$21.71M+592%
Net cash from operating activities	-$123.34M+26.4%	-$167.65M-1,507%	$11.92M+107%	-$179.87M-140%
Capital expenditures	$138K—	——	$1.24M-50.9%	$2.53M+616%
Net cash from investing activities	——	$75.65M—	——	——
Proceeds from issuance of debt	——	——	——	——
Net cash from financing activities	——	$348K-90.2%	$3.54M—	——
Net increase (decrease) in cash	$148.8M+252%	-$97.64M—	——	——
Free cash flow	-$123.48M+26.4%	-$167.8M-1,671%	$10.68M+106%	-$182.4M-143%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?: Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.